CD44在评价多形性胶质母细胞瘤预后的价值  

Evaluation of the prognostic value of CD44 in glioblastoma multiforme

作　　者：王春艳[1] 聂志[1] 崔进[2] 赵川[1] 张玲玲[2] 边莉[1] 

机构地区：[1]昆明医学院第一附属医院神经内科,云南昆明650032 [2]昆明医学院,云南昆明650031

出　　处：《云南医药》2011年第4期393-394,共2页Medicine and Pharmacy of Yunnan

摘　　要：目的多形性胶质母细胞瘤病人预后差的主要原因是治疗后易复发,因此急需找到一种对诊断、治疗及预后有帮助的一种抗体。方法回顾性病理研究近2年星形细胞瘤和多形性胶质母细胞瘤病人中CD44抗体的表达情况。结果在多形性胶质母细胞瘤病人中,肿瘤中心区CD44呈高表达,外周区呈低表达。在肿瘤病人中,CD44表达越低的其预后也越差。结论 CD44抗体对评估肿瘤的治疗及预后很有意义。Objective To develop diagnostic and prognostic markers for glioblastoma multilorme. Methods Expression of immunohistochemistry of CD44 of glioblastoma patients was used to identify potential tumor marker. Results CD44 showed expression patterns that correlated significantly with malignant g｜ioma. In particular, expression of the CD44 was elevated in more severe tumor types, and higher in tumor cores than in peripheral regions. Lower levels of CD44 expression surprisingly correlated with lower survival. Conclusion The CD44 is a promising candidate for further development as a prognostic tool.

关 键 词：多形性胶质母细胞瘤 CD44 

分 类 号：R739.4[医药卫生—肿瘤]